

CONTENTS**PAGES**

Hypertension in Pakistan: Way Forward for A Not So Silent Epidem **S-1**

PREACH Implementation Project A Socio-Ecological framework for Hypertension in Pakistan **S-2**

National Hypertension Guidelines For the Prevention, Detection, Evaluation and Management of Hypertension

| | | |
|------------|---|-------------|
| 1. | Introduction | S-6 |
| 1.1 | Global Perspective | S-6 |
| 1.2 | Pakistan Perspective | S-6 |
| 2.0 | Blood pressure (BP) | S-10 |
| 2.1 | High Blood Pressure or Hypertension | S-10 |
| 2.2 | Signs and Symptoms of BP | S-10 |
| 3.0 | Risk factors for hypertension | S-10 |
| 3.1 | Age | S-10 |
| 3.2 | Race/Ethnicity | S-10 |
| 3.3 | Overweight | S-10 |
| 3.4 | Sex | S-10 |
| 3.5 | Lifestyle Habits | S-10 |
| 3.6 | Family History | S-11 |
| 4.0 | Measurement of blood pressure (apparatuses) | |
| 4.1 | Mercury Sphygmomanometer | S-12 |
| 4.2 | Aneroid Apparatuses | S-12 |
| 4.3 | Automated Digital Sphygmomanometer | S-12 |
| 4.4 | Cuffless BP apparatuses | S-13 |
| 4.5 | The preferred device for the measurement of BP | S-13 |
| 5.0 | Accurate method to measure BP | S-14 |
| 6.0 | Types of BP Measurement Methods and Significance | S-14 |
| 6.1 | Physicians' and Nurses' BP measurement | S-15 |
| 6.2 | Single versus multiple clinic readings and accuracy of BP | S-15 |

| CONTENTS | | PAGES |
|-----------------|---|--------------|
| 6.3 | In-clinic versus post clinic BP | S-15 |
| 6.4 | Ambulatory BP monitoring | S-15 |
| 6.5 | Home BP Monitoring (HBPM) | S-15 |
| 7.0 | Risk of elevated BP | S-20 |
| 7.1 | Treatment threshold and target values | S-20 |
| 8.0 | Diagnosis of hypertension | S-22 |
| 9.0 | Diagnostic work-up | S-23 |
| 9.1 | Hypertension mediated organ damage (HMOD) | S-23 |
| 10.0 | Why treat blood pressure? | S-24 |
| 11.0 | Hypertension (Simple and with compelling indications) | S-24 |
| 11.1 | Simple hypertension (uncomplicated) | S-25 |
| 11.2 | Hypertension with compelling indication | S-25 |
| 11.3 | Threshold for diagnosis and treatment | S-25 |
| 12.0 | Global risk assessment | S-28 |
| 12.1 | Risk calculator | S-28 |
| 12.2 | Recommendations | S-28 |
| 12.3 | Implications of risk calculation | S-29 |
| 13.0 | Role of ASA for the primary prevention of CV disease | S-29 |
| 13.1 | Recommendation | S-29 |
| 14.0 | Role of statin therapy | S-30 |
| 15.0 | Life style modification | S-30 |
| 15.1 | Body Mass Index and Waist Circumference | S-30 |
| 15.2 | Exercise | S-31 |
| 15.3 | Complementary and Alternative Medicine Yoga | S-31 |
| 15.4 | Weight loss | S-32 |
| 15.5 | Salt intake | S-32 |

| CONTENTS | | PAGES |
|-----------------|---|--------------|
| 15.6 | Smoking cessation and other tobacco use | S-32 |
| 15.7 | Nutrients, vitamins and fish oil | S-33 |
| <hr/> | | |
| 16.0 | Drugs to treat hypertension | S-34 |
| 16.1 | Drug Therapy for Hypertension | S-34 |
| 16.2 | Combination Therapy (New Onset Diabetes) | S-37 |
| 16.3 | Combination Therapy (Free Versus Fixed Dose Single Pill Combination) | S-38 |
| 16.4 | Scoring Fixed Dose Combination Pill | S-38 |
| 16.5 | Resistant Hypertension | S-38 |
| 16.6 | Refractory Hypertension | S-38 |
| 16.7 | Pseudo-Resistant Hypertension | S-38 |
| <hr/> | | |
| 17.0 | White Coat Hypertension, White Coat Effect or White Coat Syndrome | S-40 |
| 17.1 | Masked Hypertension (MH) | S-41 |
| <hr/> | | |
| 18.0 | Hypertension Crises | S-42 |
| 18.1 | Severe hypertension without hypertension mediated organ damage (HMOD) | S-42 |
| 18.2 | Hypertensive urgency | S-42 |
| 18.3 | Hypertensive Emergency | S-42 |
| 18.4 | Malignant Hypertension | S-44 |
| <hr/> | | |
| 19.0 | Pregnancy and Hypertension | S-44 |
| 19.1 | Diagnosis of HTN in pregnancy | S-45 |
| 19.2 | Treatment of HTN in pregnancy | S-45 |
| 19.3 | Antihypertensive Drugs to Treat Severe Hypertension in Pregnancy | S-46 |
| <hr/> | | |
| 20.0 | Hypertension in the elderly | S-48 |
| 20.1 | Isolated systolic hypertension | S-48 |
| 20.2 | Effect of age on BP | S-48 |
| 20.3 | Drug Therapy | S-48 |
| 20.4 | Problem of orthostatic hypotension | S-48 |
| 20.5 | Problem of frailty | S-48 |
| 20.6 | Goal BP | S-49 |

| CONTENTS | | PAGES |
|-----------------|---|--------------|
| 21.0 | Hypertension in the paediatric population | S-50 |
| 21.1 | Definition | S-50 |
| 21.2 | Cuff size | S-51 |
| 21.3 | Primary and secondary causes of hypertension | S-51 |
| 21.4 | Management of hypertension in the paediatric population | S-51 |
| 21.5 | Treatment | S-52 |
| <hr/> | | |
| 22.0 | Secondary Hypertension | S-53 |
| <hr/> | | |
| 23.0 | Drug treatment of hypertension with compelling indications | S-54 |
| 23.1 | Diabetes Mellitus (DM) | S-55 |
| 23.2 | Chronic kidney disease | S-55 |
| 23.3 | Ischaemic Heart Disease | S-55 |
| 23.4 | Congestive heart failure (CHF) and asymptomatic low EF | S-56 |
| <hr/> | | |
| 24.0 | Follow-up | S-58 |
| <hr/> | | |
| 25.0 | Special concerns | S-58 |
| 25.1 | Use of sublingual drugs to lower BP acutely | S-58 |
| 25.2 | Use of anxiolytics as first line antihypertensive therapy | S-58 |
| <hr/> | | |
| 26.0 | Summary | S-59 |
| <hr/> | | |
| 27.0 | Case Vignettes | S-60 |
| <hr/> | | |